Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | MAFG | O15525 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16085534 | 0.94 | SMN1; SMN2 (0.79) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16060376 | 0.92 | SMN1; SMN2 (0.76) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085502 | 0.92 | SMN1; SMN2 (0.81) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085535 | 0.92 | SMN1; SMN2 (0.81) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085529 | 0.92 | SMN1; SMN2 (0.75) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085446 | 0.90 | SMN1; SMN2 (0.78) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL29419037 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085530 | 0.88 | SMN1; SMN2 (0.92) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30440736 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085609 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014145642-A9 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014145642-A9 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014145642-A2 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145642-A2 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8728631-B2 | Dendrimer compound and organic luminescent device employing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | NFE2L2, KEAP1, GSTK1 | SMN1; SMN2 2617/4885POLB 932/4885MAFG 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.